LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Low-Cost, Simple-to-Use, Ultrafast Point-of-Care COVID-19 Test to Provide RT PCR Results in 8 Minutes

By LabMedica International staff writers
Posted on 09 Oct 2020
Print article
Image: Close-up of early Rover photothermal PCR prototype (Photo courtesy of Rover Diagnostics)
Image: Close-up of early Rover photothermal PCR prototype (Photo courtesy of Rover Diagnostics)
A new low-cost, simple-to-use, ultrafast point-of-care test for COVID-19 aims to provide reverse transcription polymerase chain reaction (RT PCR) results in just eight minutes, faster than any other test of its kind, with targeted accuracy to match laboratory-based tests.

The promising new COVID-19 rapid-testing technology platform has been developed by Rover Diagnostics (New York, NY, USA) and Columbia Engineering (New York, NY, USA). Rover’s ultrafast, portable PCR technology is based on two breakthroughs in science and engineering and it meets all the conditions for successful point-of-care PCR. First, it uses microfluidic sample preparation developed by Prof. Sam Sia’s lab at Columbia University’s Dept. of Bioengineering. This technology allows Rover to eliminate expensive, complex sample prep equipment in favor of a small, disposable chip.

Secondly, the platform uses a new approach to thermal cycling that bypasses the standard Peltier device which requires 40-60 minutes for amplification. Instead of radiant heat coming from outside the vial or well, the platform use photothermal gold nanoparticles to generate heat from inside. The result is thermal cycling that is 10x faster and uses 100x less energy than is possible today. Rover aims to combine these two technologies into an easy-to-use, sample-to-answer instrument. Furthermore, Rover will integrate HIPAA-compliant cloud access to allow for instant notification and large-scale data analysis. Rover’s COVID-19 rapid-testing technology platform has been selected by the National Institutes of Health (NIH) to enter Phase 1 of the Rapid Acceleration of Diagnostics (RADx) initiative to support new COVID-19 testing technologies.

“We were determined to develop a testing platform for all kinds of viruses that is cheap, reliable, and accessible to everyone,” said Sia, an innovator in point-of-care blood tests, wearable sensors, and implantable devices. “With Rover, we can now perform thermal cycling, which is the backbone of high-performing DNA and RNA testing, several times faster.”

“We are expanding our testing of clinical samples and bringing together additional resources and expertise to finalize the design and speed to manufacturing. The NIH RADx initiative is accelerating our progress to bring the fast PCR platform to the widest possible good,” added Sia.

Related Links:
Rover Diagnostics
Columbia Engineering


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
COVID-19 Rapid Test
AQ+ COVID-19 Ag Rapid Test

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more